Silexion Therapeutics Corp (SLXN): Total Liabilities
$4.61M
As of 2025-12-31
$4.20M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.61M | -32.7% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $6.85M | +203.9% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $2.25M | n/a | 2025-03-18, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | 2025-12-31 | $4.61M | -32.7% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $8.48M | +104.1% |
| Creative Medical Technology Holdings, Inc. (CELZ) | 2025-12-31 | $284.9K | -13.1% |
| Exozymes Inc. (EXOZ) | 2025-12-31 | $2.57M | -1.5% |
| Calidi Biotherapeutics, Inc. (CLDI) | 2025-12-31 | $5.10M | -58.3% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $15.56M | +56.7% |
| Greenland Mines Ltd (GRML) | 2025-12-31 | $129.8K | -89.8% |
| Eloxx Pharmaceuticals, Inc. (ELOX) | 2025-12-31 | $17.18M | -37.1% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $8.71M | +16.8% |
Compare SLXN, VIVS, CELZ, EXOZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗